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Abstract
Introduction: Current low (stress) dose corticosteroid regimens may have therapeutic advantage in severe sepsis
and septic shock despite conflicting results from two landmark randomised controlled trials (RCT). We
systematically reviewed the efficacy of corticosteroid therapy in severe sepsis and septic shock.
Methods: RCTs were identified (1950-September 2008) by multiple data-base electronic search (MEDLINE via OVID,
OVID PreMedline, OVID Embase, Cochrane Central Register of Controlled trials, Cochrane database of systematic
reviews, Health Technology Assessment Database and Database of Abstracts of Reviews of Effects) and hand search
of references, reviews and scientific society proceedings. Three investigators independently assessed trial inclusion
and data extraction into standardised forms; differences resolved by consensus.
Results: Corticosteroid efficacy, compared with control, for hospital-mortality, proportion of patients experiencing
shock-resolution, and infective and non-infective complications was assessed using Bayesian random-effects
models; expressed as odds ratio (OR, (95% credible-interval)). Bayesian outcome probabilities were calculated as the
probability (P) that OR ≥1. Fourteen RCTs were identified. High-dose (>1000 mg hydrocortisone (equivalent) per
day) corticosteroid trials were associated with a null (n = 5; OR 0.91(0.31-1.25)) or higher (n = 4, OR 1.46(0.73-2.16),
outlier excluded) mortality probability (P = 42.0% and 89.3%, respectively). Low-dose trials (<1000 mg
hydrocortisone per day) were associated with a lower (n = 9, OR 0.80(0.40-1.39); n = 8 OR 0.71(0.37-1.10), outlier
excluded) mortality probability (20.4% and 5.8%, respectively). OR for shock-resolution was increased in the low
dose trials (n = 7; OR 1.20(1.07-4.55); P = 98.2%). Patient responsiveness to corticotrophin stimulation was non-
determinant. A high probability of risk-related treatment efficacy (decrease in log-odds mortality with increased
control arm risk) was identified by metaregression in the low dose trials (n = 9, slope coefficient -0.49(-1.14, 0.27);
P = 92.2%). Odds of complications were not increased with corticosteroids.
Conclusions: Although a null effect for mortality treatment efficacy of low dose corticosteroid therapy in severe
sepsis and septic shock was not excluded, there remained a high probability of treatment efficacy, more so with
outlier exclusion. Similarly, although a null effect was not excluded, advantageous effects of low dose steroids had
a high probability of dependence upon patient underlying risk. Low dose steroid efficacy was not demonstrated in
corticotrophin non-responders. Further large-scale trials appear mandated.
Introduction
In 1974, Weitzman and Berger reviewed the clinical trial
design of studies reporting corticosteroid use in bacterial
infections over the previous 20 years because of the con-
troversial role of the therapeutic use of corticosteroids
in acute infections [1]. It is ironic that 34 years later a
similar sentiment was echoed: “For more than five dec-
ades, no other adjunctive therapy has been more consis-
tently debated than the use of corticosteroids for severe
sepsis and septic shock” [2]. A contemporaneous review
concluded that the role of glucocorticoid therapy in
intensive care remained uncertain [3]. In 1995, two
meta-analyses found no benefit for high-(pharmacologi-
cal)-dose corticosteroids in sepsis and septic shock [4,5]
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efit for long courses of low-(stress) [7]-dose corticoster-
oids. This benefit was either qualified: pending the
results of the Corticosteroid Therapy of Septic Shock
(CORTICUS) [8] study, clinical equipoise remained for
the issues of adreno-corticotrophin (ACTH) administra-
tion, cortisol testing, and the therapeutic use of hydro-
cortisone [9]; or more definitive: ‘...a beneficial therapy
to critically ill patients in septic shock’ [10]. That the
confirmatory [11] phase III CORTICUS study [8] was
‘somewhat disappointing’ [12] undoubtedly reflects this
history of therapeutic uncertainty. Current guidelines
advocate a role for intravenous hydrocortisone in adult
septic shock patients who are poorly responsive to fluid
and vasopressor therapy and, in the apparent absence of
a mortality effect dependent on ACTH responsiveness,
attention has been directed to the more rapid time-reso-
lution of shock with corticosteroids [13,14].
Thus the question still remains: what is the evidence,
post CORTICUS [8], for the efficacy of corticosteroids
in severe sepsis and septic shock? We undertook a sys-
tematic review and quantitative analysis of randomized
controlled trials (RCT) addressing corticosteroid efficacy
in severe sepsis and septic shock, updating [15] previous
studies [6,7]. As the question of further large-scale trials
to assess corticosteroids in septic shock has currently
been canvassed [16], in particular the efficacy at high
mortality risk [12], we addressed the risk-related efficacy
of steroids within the trials considered [17] and esti-
mated the predictive distribution for the underlying
effect in new studies [18].
Materials and methods
Trial selection
Randomised controlled trials in critically ill patients
evaluating corticosteroid therapy versus no corticoster-
oid therapy in severe sepsis or septic shock were consid-
ered for inclusion. Only trials reporting mortality were
included. We excluded: studies reporting only physiolo-
gical endpoints (for example, changes in immunological
variables); descriptive studies; retrospective cohort stu-
dies; studies in the pediatric population; and studies
exclusively reporting series of meningitis, typhoid fever
and pneumonia where sub-set analyses of patients of
interest (for this meta-analysis) were not reported.
Where there was missing data or ambiguity of data pre-
sentation, attempts were made to contact the study
author(s) to resolve these issues.
Search strategy and quality assessment
An extensive computerized literature search was per-
formed (SR) for the period of 1950 to September 2008
using the National Library of Medicine MEDLINE via
OVID, OVID PreMedline, EBSCO Cinahl, OVID
Embase, Cochrane Central Register of Controlled trials,
Cochrane database of systematic reviews, American Col-
lege of Physicians Journal Club, Health Technology
Assessment Database and Database of Abstracts of
Reviews of Effects. We restricted the search to studies
on adult human populations and used the Mesh,
Embase and Cinahl thesaurus in addition to free text
searching. The following terms were identified as the
most relevant: sepsis or bacteremia or fungemia or
pneumonia or septicemia or septic shock narrowed
down with the terms hydrocortisone or corticosteroids
or adrenal cortex hormones or steroids. The set was
then further limited to randomised controlled trials or
clinical trials or multicenter study and trials published
in English. A detailed search strategy is provided in
Additional file 1.
We reviewed the abstracts of trials generated by the
electronic search and the full text of trials pertaining to
corticosteroids in sepsis and septic shock were retrieved
for a more detailed evaluation. Review articles were
examined to identify additional trials. In addition a hand
search of the proceedings of scientific meetings of the
following journals was performed: American Journal of
Respiratory and Critical Care Medicine, Chest, Critical
Care Medicine, European Respiratory Journal, Intensive
Care Medicine and Thorax.
Quality assessment
Three investigators (JLM, PL G ,a n dA B )r e v i e w e ds t u -
dies fulfilling inclusion criteria and pre-defined variables
and outcomes were abstracted into standardized data
abstraction forms. Quality assessment on the published
studies was performed in an un-blinded fashion by two
investigators (JLM, PLG) using the 11-point quality
score of Cronin and colleagues [4]. Where there were
differences in scoring, a consensus was reached.
Extracted data was separately entered, reviewed and ver-
ified by two investigators (JLM, PLG) prior to analysis.
Outcome measures
The primary outcome was mortality assessment at hos-
pital discharge. Secondary outcomes were resolution of
shock (or withdrawal of inotropes) at 7 to 28 days and
corticotrophin responsiveness, secondary infections and
non-infective (gastro-intestinal bleeding and new-onset
hyperglycemia) complications.
Definitions
Severe sepsis and septic shock were defined after the
1992 American College of Chest Physicians and Society
of Critical Care Medicine Consensus Conference [19].
Pre-1992 studies were reviewed to establish consistency
with this definition. Secondary infections were defined
generally as a positive culture from a normally sterile
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tions for secondary infections would be subject to revi-
sion; for example, the use of quantitative cultures in
more recent calendar years [20]. Shock resolution was
defined as a stable hemodynamic state for a period of
24 hours or more after weaning of vasopressor support.
Corticosteroid dose was converted into hydrocortisone
equivalents (mg) and expressed as total maximum rea-
lizable dose [20] accounting for total time of exposure
(therapeutic dose-time and tapering). Where patient
corticosteroid dose-time schedule was unavailable due
to death and/or reporting, we used median survival time
from the published Kaplan-Meier curve.
Statistical analysis
The effect of corticosteroids compared with control on
mortality; the proportion of patients experiencing
shock-resolution at defined times; and infective and
non-infective complications were assessed using Baye-
sian random-effects models [21], via WinBUGS software
[22] using three simultaneous runs of the program with
disparate starting values. The first 10,000 iterations were
discarded and results were reported as the posterior
median odds ratio (OR) with 95% credible intervals
(CrI) on the basis of a further 100,000 iterations. As
argued previously [20], the hazard ratio would have
been the preferred metric for mortality effect due to
varying event times. However, due to the variability in
intra-trial reporting, this was not feasible. As the hazard
ratio may be approximated from the OR [23], we chose
the OR as an appropriate metric [24]. Bayesian para-
meter estimates, as opposed to frequentist, are probabil-
ity distributions and hence there is no contradiction in
computing both (i) a (median) point estimate and CrI
and (ii) the posterior probability (P) that, say, the OR is
more than 1 [25,26]. That is, “Bayesian methodology
also allows us to make statements about the probability
that the ORs are greater than 1 in cases in which the
associated 95% CrI includes 1” [27]. A probability of
50% suggests a null effect, while P of at least 90% sig-
nifies harm and P less than 10% indicates benefit for the
mortality, infective and non-infective endpoints and vice
versa for the shock reversal endpoint [28]. Analysis was
undertaken by stratifying between ‘high-dose’ and ‘low-
dose’ corticosteroid therapy, as in Annane and collea-
gues [6] and after the categorization of daily treatment
doses of hydrocortisone by Marik (high-dose corticoster-
oid >1,000 mg per day) [29].
Bayesian meta-regression [21] was used to determine
the relation between log odds mortality and (i) average
patient age and (ii) control-arm risk, as log-odds mortal-
ity [17,24]. The slope (b) with 95% CrI and the probabil-
ity that b ≥ 0( Pb) were presented. Heterogeneity was
presented as the standard deviation, τ, between studies
[30]; τ close to 0 indicates little heterogeneity, τ =0 . 5
indicates moderate and τ > 1 reflects substantial hetero-
geneity [18].
For heuristic purposes we separately estimated: (i)
pooled estimates with the Schumer [31] and Cooperative
Study Group (CSG) [32] studies removed in a sensitivity
analysis due to previous identification of the former as a
potential outlier [7] and the remoteness of the latter
1963 trial from current therapeutic regimens; (ii) certain
parameters of clinical import in the risk difference
metric [21], albeit this metric may suffer from potential
bias with varying time to event [24]; (iii) the mortality
OR and probability (P)t h a tt h eO Rw a s1o rm o r ei n
the predictive distribution (that is, in the next ‘new’
study); (iv) the mortality OR for hypothesized studies of
size 2,000 and 4,000 patients; (v) the Bayesian predictive
P-value that the CORTICUS trial [8] was inconsistent
with the other trials of the low-dose corticosteroid
group; that is, the CORTICUS study was omitted from
analysis (leaving n = 7 trials) and a replicate study of
t h es a m es i z ea st h eC O R T I C U Ss t u d yw a sd r a w n ,w i t h
a replicate baseline, and a new treatment effect was
established based upon the predictive distribution. A
Bayesian predictive P-value was subsequently obtained,
expressing the probability that the future study would
be as ‘extreme’ as that observed.
Publication and the associated phenomenon of small-
study bias were addressed using the approach of Peters
and colleagues [33] via contour-enhanced funnel plots;
formal quantitative testing for small-study-bias was per-
formed using the approach of Harbord and colleagues
[34], which has effective properties in the presence of
appreciable heterogeneity. Implementation was via the R
package ‘meta’ [35] and user-written routines.
Results
Using multiple electronic searches, 1,843 abstracts of
published papers were identified (including duplicates).
A review of these abstracts (JLM, PLG) identified 115
papers of potential interest including review papers. The
p u b l i s h e dt e x to f3 1‘randomized’ clinical trials, includ-
ing seven abstracts from proceedings of scientific meet-
ings, were further reviewed (JLM, PLG, AB): two were
excluded on the basis of reporting from previous trials,
one reported no mortality outcome data and one used
pseudo-randomization. A further 13 studies, including
four abstracts-only were excluded for reasons given
in Table 1. The final cohort was of 14 trials
[8,31,32,36-46], including two abstracts from the reports
of scientific meetings; 11 of the studies had been consid-
ered by previous meta-analyses [4-6,10] and the three
remaining studies [8,42,44] were post-2004, the publica-
tion date of the two comparator meta-analyses [6,7]
(Figure 1 and Table 2). The trial patient size varied
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was 1,991, of mean age 55 years and 66% male. Total
corticosteroid dosage in the high-dose cohort ranged
from 7,000 to 42,000 hydrocortisone-equivalent mg over
one to three days, whereas in the low-dose cohort,
dosage was 856 to 2,175 hydrocortisone-equivalent mg
o v e r2t o1 0d a y st r e a t m e n tw i t h0t o1 4d a y so ft a p e r -
ing (Table 3). Average high- and low-dose control arm
mortalities were 47% and 54%, respectively. Further
characteristics of the trials are given in Tables 2 and 3.
The primary outcome of hospital mortality was avail-
able in six studies [8,32,36,39,43,46]; the other studies
had recorded 28- or 30-day mortality and one study
recorded 14-day mortality (Table 2). Sepsis and shock
definitions of trials completed before 1992
[31,32,38,41,43,46] were generally consistent with defini-
tions of the American College of Chest Physicians and
Society of Critical Care Medicine Consensus Conference
on sepsis and organ failure, albeit the two trials published
in 1971 [41] and 1963 [32] used ‘life threatening infec-
tions’ as a criteria (Table 2). Of interest, trials before
1998 were predominantly reported from the USA; after
1997, they were from European and other non-USA sites.
Trial patient data by outcomes (hospital mortality;
shock-reversal; corticotrophin-responsiveness; shock
reversal by corticotrophin-responsiveness; and secondary
complications, as infectious, gastro-intestinal bleeding
and new-onset hyperglycemia) are shown in Table 4.
Mortality outcome
Neither the low-dose nor high-dose cohort showed a sig-
nificant steroid treatment effect for the mortality OR,
although there was modest evidence of benefit in the
low-dose cohort (P = 20.4%) (Table 5 and Figure 2). The
odds of mortality (four studies [8,36,42,45]), for both cor-
ticotrophin responders and non-responders was not sig-
nificantly different compared with control (Table 5).
Table 1 Study exclusions
Study Year
published
Reason for exclusion
Wagner and colleagues
[78]
1955 Description of pneumonia therapy only with no severity stratification. Allocation by ‘history number’
Thompson and
colleagues [79]
1976 Abstract; nine of 60 patients with cardiogenic shock; no subset analyses. Post-randomization exclusion of
4 patients
Lucas and Ledgerwood
[80]
1984 Open-label study; pseudo-randomization by hospital number
VASSCS [81] 1987 Predominantly sepsis patients with no subgroup of shocked patients. No timing of fluid bolus with
respect to reported hypotension
Schattner and colleagues
[82]
1997 pseudo-randomization of patients with ‘early sepsis’
Keh and colleagues [60] 2003 Cross-over placebo study in septic shock
Confalonieri and
colleagues [83]
2005 Community acquired pneumonia study; no subset analyses for shocked patients
Rinaldi and colleagues
[84]
2006 Post randomization exclusion of 15 patients; 3 with septic shock
Huh and colleagues [85] 2006 Abstract; two hydrocortisone arms; no concurrent placebo arm reported
Loisa and colleagues [86] 2007 Two hydrocortisone arms; no concurrent placebo group
Nawab and colleagues
[87]
2007 Abstract; severe community acquired pneumonia, no subset analysis; outcomes today-7 only
Cicarelli and colleagues
[88]
2007 Unspecified post-randomization exclusion of ‘all patients who progressed to refractory septic shock’
Kurugundla and
colleagues [89]
2008 Abstract; ICU outcomes reported only
VASSCS, Veterans Administration Systemic Sepsis Cooperative Study.
Figure 1 Flowchart for identification of studies on
corticosteroids in severe sepsis and septic shock; number of
trials evaluated at each stage of the systematic review.
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Page 5 of 15A contour-enhanced funnel plot showed no obvious
asymmetry in terms of a lack of small studies with a
null or adverse steroid effect (Figure 3), this was not
rejected (at the 0.1 level) using the quantitative
approach of Harbord and colleagues [34] (P = 0.146).
T h el o w - d o s es t u d i e ss h o w e dad e g r e eo fa s y m m e t r yo f
the contour-enhanced funnel plot (Figure 4), but the
quantitative estimate did not confirm this (P = 0.113).
Shock reversal
Median vasopressor time (six studies [8,36,37,39,42,47])
ranged from 2 to 7 days for steroid-treated patients and
5 to 13 days for placebo. With respect to the number of
patients experiencing shock reversal, there was no clear
steroid treatment-effect (overall OR included 1) for
high-dose studies (n = 2). However, there was a high
probability of benefit for the low-dose cohort; moderate
heterogeneity being present (Figure 5 and Table 5).
Odds of shock-reversal were not substantially different
for corticotrophin non-responders or responders; how-
ever, both had a high probability of benefit (Table 5).
Metaregression
Univariate metaregression of average age against log
odds mortality yielded no significant effects although Pb
was high and the slope positive for both low- and high-
dose cohorts. This indicated some evidence that, on
average, older study participants had increased odds of
mortality under steroid treatment versus control (Table
5). Similarly, although the metaregression of underlying
control-arm risk against log odds mortality yielded no
significant effects, for the low-dose cohort, Pb was small
and the slope negative, indicating a high probability that
as the underlying risk of mortality increased the log
odds mortality under steroid treatment decreased (Table
5). The removal of the CSG study [32] attenuated the
negative slope of the line. In the risk difference metric,
the intersection of the (meta)regression line with the
line of null effect (’cross-over’ point) occurred for age at
62 years and for control-arm mortality at 44%.
Complications of therapy
The complications of therapy were secondary infections,
gastro-intestinal bleeding and steroid-induced hypergly-
cemia. No overall or low- or high-dose effects were
demonstrated for any of the pooled endpoints (Table 5).
Heuristics
The considerable heterogeneity of the high-dose cohort
(τ = 1.00, 95%CrI = 0.42 to 1.89) was diminished by the
removal from analysis of the Schumer study [31] (Table
5), an effect previously noted by Minneci and colleagues
[7]. This also lead to a high probability of harm in the
high-dose studies (P = 89.3%) although the CrI for the
T
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Page 8 of 15OR still included 1. Removal of the CSG study [32] from
analysis resulted in reduced heterogeneity among the
low-dose studies (Table 5) and a high probability of
benefit in the low-dose studies (P =5 . 8 % )a l t h o u g ht h e
CrI for the overall OR just included 1.
I nt h er i s kd i f f e r e n c em e t r i c the absolute risk differ-
ence (treatment versus control) for nine trials in the
low-dose cohort was -0.047(95%CrI = -0.197 to 0.077; P
(RD > 0) = 21.9%); and for eight trials (CSG trial
excluded [32]) was -0.072 (95%CrI = -0.202 to 0.018; P
(RD > 0) = 5.3%), similar to the 6.6% reported by
Annane and colleagues [48]. The mortality OR in the
predictive distribution (from eight trials) was 0.703 (95%
CrI = 0.156 to 2.198; P(OR > 1) = 19.9%). For hypothe-
sized studies of size 2,000 and 4,000 patients, the mor-
tality ORs were predicted to be 0.724 (95%CrI = 0.184
to 2.108) and 0.726 (95%CrI = 0.184 to 2.096), respec-
tively. The Bayesian predictive P-value, reflecting the
inconsistency of the CORTICUS study [8] with the
remaining trials (n = 7; CSG trial excluded [32]) was
0.074.
Discussion
Despite the disappointment of the CORTICUS [8] trial,
our review suggests a modest to high probability (80%
to 98%) of efficacy for low-dose steroids with respect to
both mortality and shock reversal; the mortality effect
being risk-related (Table 5). These probabilities are to
be interpreted in the context of CrI spanning the null
for all estimates (see Statistical analysis, above). We
found no strong evidence for the determinacy of ACTH
responsiveness nor complications of corticosteroid ther-
apy. This being said, it is of interest to note the admoni-
tory impact of the CORTICUS study on recent
summary statements of sepsis management
[2,3,13,29,49]. Consistent with previous meta-analyses
[6,7] we found null or adverse effects of high-dose ster-
oids; the probability of therapeutic complications being
low (Table 5).
The use of prolonged low-dose corticosteroid was
justified in the landmark Annane and colleagues trial
on the basis that “severe sepsis may be associated with
relative adrenal insufficiency or systemic inflammation-
induced glucocorticoid receptor resistance...” [36].
Apropos of this statement, it is instructive to note that
the primary aim of the CORTICUS study was 28-day
mortality in patients not responding to corticotrophin
[8]. A recent review of corticosteroid insufficiency in
the critically ill has suggested that in states where such
insufficiency [50] is located “within the tissue itself...
the adrenal gland function could be normal... it would
be impossible to diagnose this state on the basis of
serum or even tissue levels of glucocorticoids...[and]...
treatment would require supraphysiological levels of
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Page 9 of 15glucocorticoids” [51]. The inability in the current
meta-analysis to demonstrate treatment efficacy with
respect to mortality and shock-reversal based upon
corticotrophin responsiveness is in agreement with
Minneci and colleagues [7] and suggests both that
tests of the latter to direct treatment regimens are mis-
placed and that the notion of adrenal insufficiency in
severe sepsis and septic shock is problematic [52]; a “...
hardly definable disease entity or syndrome...” [53].
Of the seven trials reporting shock-reversal
[8,36,37,39,40,42,44], time to the latter end-point was
the primary study end-point in three [37,39,42]. All pub-
lished studies used time-to-event analysis based upon
conventional Kaplan-Meier estimates, censoring those
who died and/or those in whom vasopressor therapy
could not be withdrawn at time of assessment. However,
such analyses are problematic, because they ignore the
competing risk of those who died and/or those in whom
vasopressor therapy could not be withdrawn. In the pre-
sence of competing risks Kaplan-Meier estimates cannot
be interpreted as probabilities [54,55]. Under the
conditions of competing risks, the probability of an
event is more appropriately estimated by the cumulative
incidence function, which, for the particular event of
interest, is a function of the hazards of all the competing
events and not solely of the hazard of the event to
which it refers. Hypothesis tests for the cumulative inci-
dence function do not necessarily equate with the famil-
iar log-rank test [56].
How then are we to understand these favourable
effects of low-dose corticosteroids? Glucocorticoid
action on inflammation [57], vascular reactivity [58] and
interactions between corticosteroids and ‘signalling path-
ways’ [59] may explain the salutary effects in sepsis [60];
anti-inflammatory and coagulation effects would appear
to be differentially dose dependent [61]. Low or stress
doses of hydrocortisone, as currently prescribed, are not
replacement or physiological doses; they generate
plasma cortisol levels greater than 2,500 nmol/l, in
excess of the usual upper limits (1,000 to 1,500 nmol/l)
of patients in septic shock [42,60,62]. The presumed
immune-modulation [63] of these prolonged low-dose
Table 5 Outcome effect estimates
Outcome N OR (95%CrI) P (%) τ (95%CrI) b (95%CrI) Pb(%)
Mortality
High dose 5 0.912 (0.313 to 1.253) 42.0 1.00 (0.42 to 1.89)
High dose excluding Schumer [31] 4 1.406 (0.727 to 2.614) 89.3 0.25 (0.01 to 1.40)
Low dose 9 0.796 (0.396 to 1.386) 20.4 0.65 (0.23 to 1.44)
Low dose excluding CSG [32] 8 0.706 (0.371 to 1.096) 5.8 0.39 (0.04 to 1.15)
Corticotrophin responders* 4 0.882 (0.285 to 2.073) 36.4 0.49 (0.02 to 1.78)
Corticotrophin non-responders* 4 0.831 (0.334 to 1.971) 28.0 0.43 (0.02 to 1.69)
Shock-reversal
High dose 2 1.078 (0.227 to 6.311) 54.9 1.39 (0.06 to 1.93)
Low dose 7 1.999 (1.069 to 4.55) 98.2 0.57 (0.04 to 1.62)
Corticotrophin responders* 3 1.830 (0.499 to 7.845) 86.7 0.87 (0.05 to -1.92)
Corticotrophin non-responders* 3 1.845 (0.637 to 7.267) 91.9 0.55 (0.02 to 1.86)
Meta-regression (log odds mortality)
Average age High dose 4 0.777 (0.285 to 2.426) 27.3 0.72 (0.04 to 1.87) 0.60 (-0.23 to 1.51) 94.52
Excl Schumer [31] 3 1.390 (0.399 to 4.872) 77.0 0.66 (0.03 to 1.90) 0.10 (-1.57 to 1.74) 58.05
Low dose 6 0.658 (0.334 to 1.223) 7.6 0.36 (0.02 to 1.51) 0.05 (-0.10 to 0.18) 80.53
Underlying risk High dose 5 0.943 (0.292 to 3.049) 45.4 1.14 (0.46 to 1.49) 0.23 (-1.71 to 2.58) 60.98
Excl Schumer [31] 4 1.372 (0.596 to 3.249) 82.9 0.38 (0.01 to 1.74) -0.09 (-1.31 to 1.42) 41.47
Low dose 9 0.752 (0.389 to 1.291) 14.5 0.57 (0.17 to 1.37) -0.49 (-1.14 to 0.27) 7.80
Excl CSG [32] 8 0.676 (0.347 to 1.076) 4.9 0.40 (0.03 to 1.23) -0.28 (-0.88 to 0.50) 19.08
Odds of the following complications (corticosteroids versus
control)
Superinfection High dose 4 1.127 (0.364 to 3.924) 62.2 0.55 (0.02 to 2.85)
Low dose 6 0.955 (0.388 to 1.749) 43.6 0.46 (0.03 to 1.62)
GI bleeding High dose 3 0.824 (0.167 to 3.186) 37.3 0.74 (0.03 to 1.90)
Low dose 5 1.103 (0.379 to 3.031) 59.6 0.58 (0.02 to 1.84)
Hyperglycemia High dose 3 1.012 (0.244 to 4.266) 50.8 0.64 (0.03 to 1.88)
Low dose 3 1.430 (0.155 to 3.985) 57.4 0.87 (0.05 to 1.93)
*all studies were low dose; CI, confidence interval; CSG, Cooperative Study Group; GI, gastro-intestinal; N, number of studies reporting data for that endpoint; NA,
not applicable; OR, odds ratio. Excl Sch = Excluding Schumer [31]; Excl CSG = Excluding CSG [32]
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Page 10 of 15Figure 2 Corticosteroid mortality effect (OR), stratified by high
(upper panel) or low (lower panel) dose steroid regimen;
forest plot representation of the effect. The vertical straight line
denotes null effect (odds ratio (OR) = 1). The individual points
denote the OR for each study and the lines on either side the 95%
Bayesian credible intervals (CrI).
Figure 3 Contour-enhanced funnel plot of mortality odds
versus standard error for all trials (n = 14). Vertical axis, standard
error; horizontal axis, mortality odds (log scale). The ‘contours’, based
upon a two-sided P value, are the conventional levels (not ‘pseudo’
confidence intervals) of statistical significance (<0.01, <0.05, <0.1) for
the primary studies and are independent of the pooled estimate (if
the pooled estimate is biased, the contours are not affected) [33].
Figure 4 Contour-enhanced funnel plot of mortality odds
versus standard error for low-dose corticosteroid trials (n =9 ) .
Vertical axis, standard error; horizontal axis, mortality odds (log
scale). The ‘contours’, based upon a two-sided P value, are the
conventional levels (not ‘pseudo’ confidence intervals) of statistical
significance (<0.01, <0.05, <0.1) for the primary studies and are
independent of the pooled estimate (if the pooled estimate is
biased, the contours are not affected) [33]
Figure 5 Corticosteroid shock-reversal effect (OR), stratified by
high (upper panel) or low (lower panel) dose steroid regimen;
forest plot representation of the effect. The vertical straight line
denotes null effect (odds ratio (OR) = 1). The individual points
denote the OR for each study and the lines on either side the 95%
Bayesian credible intervals (CrI).
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Page 11 of 15regimens underpins the rationale of critical illness-
related corticosteroid insufficiency [14,29]. This being
said, the Annane and colleagues [36] trial used a fixed
seven-day steroid course without tapering and claimed
efficacy and no difference in the complication rates was
evident between the high-and low-dose cohorts in both
the current and Annane and colleagues’ meta-analyses
[6]. As mentioned in commentary [64], differences in
control group mortalities of the Annane and colleagues
[36] and CORTICUS [8] trials may explain differing out-
comes on the basis of risk-related treatment effects. The
latter were persuasively demonstrated in the current
meta-analysis. The estimate of mortality risk at which
low-dose corticosteroids began to exhibit a treatment
effect, 44%, was clinically plausible given the range of
control-arm mortalities of 30 to 93%. Such demonstra-
tion, using appropriate Bayesian methodology [17,24],
represents a novel insight into critical care therapeutic
efficacy.
Critique of methodology
Our analytic approach was to consider the two treat-
ment cohorts, high- and low-dose corticosteroid, sepa-
rately; we did not produce an overall treatment effect on
the basis that both the treatment intention and effective
(daily) corticosteroid dose of the two cohorts were quite
disparate. An alternate approach would have been to
consider all trials (n = 14) with total hydrocortisone
dose or calendar year as effect-moderators. In the
absence of individual patient data, such analyses, with
only 14 studies, have low power.
Secondary outcome analysis was beset by selection
bias in reporting [65], as witnessed by study numbers in
Table 5; parameter estimates may be biased under such
circumstances. The study list addressing low-dose corti-
costeroid mortality efficacy (n = 9) included a single
study [32] in 1963, the others being from the period
1996 to 2005 (Figure 2). Plausible estimates of current
therapeutic efficacy would suggest analysis excluding the
former study, the result of which was to reduce hetero-
geneity of the mortality effect by 40% and to reveal a
probability of corticosteroid efficacy of 94.2% (Table 5).
The single-investigator single-centre Schumer study,
conducted over a prolonged eight-year period, has been
previously subject to substantive critique [7] and recent
cautions regarding extended recruitment time [66] and
inference from single-center studies [67] merits its con-
sideration as an outlier.
That the inclusion of the large but null-effect CORTI-
CUS trial [8] in the current meta-analysis did not extin-
guish a probable treatment effect deserves comment.
The impact of the single large trial is undoubted, but
the evidence produced by such a trial may be “less reli-
able than its statistical analysis suggests” [68]. We
adopted a random effects methodology [69] in the pre-
sence of moderate between study heterogeneity (τ, Table
5); under these conditions large studies may have little
impact upon a meta-analysis [70] and there may be
virtue in (clinical) heterogeneity [71]. The degree of
asymmetry of the contour-enhanced funnel plot in the
low-dose cohort (see Results, Mortality outcome, above)
raises concerns about a random effects methodology
[69], but there was no quantitative evidence of small-
study effects (at the 0.1 level) and the number of studies
was small. In the presence of sparse data and moderate
heterogeneity (Table 5), the interpretation of funnel plot
asymmetry is problematic [34,72] and exploration of the
reasons for such heterogeneity is the preferred analytic
focus [34].
With respect to the efficacy of corticosteroids in
severe sepsis and septic shock, the divergent positions
represented by the Annane and colleagues [36] and
CORTICUS [8] trials remain unresolved. Two recent
(calendar year 2009) updates [48,73] of previous meta-
analyses [6,7] also merit comment. Both of the updated
meta-analyses, using frequentist methodology, found
efficacy of low-dose prolonged corticosteroids with
respect to the mortality effect, Annane and colleagues
[48] found a relative risk of 0.84 (95% confidence inter-
val (CI) = 0.72 to 0.97; P = 0.02) and Minneci and col-
leagues [73] found an OR of 0.64 (95% CI = 0.45 to
0.93; P = 0.02), and shock reversal, the latter effect con-
sistent with the estimates of the current study (Table 5).
Study inclusions in these meta-analyses differed and
were not the same as in our meta-analysis, which
a d o p t e dar i g o r o u se x c l u s i o np o l i c y( T a b l e1 ) .T h ef r e -
quentist meta-regression methods used by both meta-
analyses [48,73] to estimate the risk-related treatment
efficacy of steroids are problematic [17,24]. Although
such methods may identify putative risk related treat-
ment effects in meta-analyses they fail to allow for both
regression to the mean (the difference between outcome
and baseline being correlated with baseline) and the sto-
chastic nature of the control rate (regression dilution
bias). The stochastic characteristic of the control rate is
also not addressed as the expected response in (ordin-
ary) linear regression is conditional upon independent
(fixed) variables and there is no inherent accounting for
the random error in estimation of this control rate.
Such problems are overcome by the use of Bayesian
methods [17,24].
Both meta-analyses were judicious in their conclusions
about treatment efficacy and this was reiterated by an
accompanying editorial [74]. However, neither study was
able to attend to this uncertainty in a tangible manner.
This is precisely what our Bayesian analysis quantifies:
what was the probability of treatment efficacy. For
example, our analysis demonstrated that the probability
Moran et al. Critical Care 2010, 14:R134
http://ccforum.com/content/14/4/R134
Page 12 of 15of adverse mortality outcome with low-dose corticoster-
oids (outlier excluded) was 5.8% (Table 5). The omission
of such a probability statement cannot be justified by an
appeal to “the nominal P values for these outcomes
were very close to 0.05....” [48]. We have previously cau-
tioned the against interpretation of 95% CI (and asso-
ciated frequentist P values) as probability statements
[75]. Furthermore, neither meta-analysis reported
exploration of estimates from a predictive distribution,
which may be considered as a more appropriate future
treatment summary than the mean effect [18]. Such a
capacity recommends Bayesian methodology, although
meta-analytic prediction intervals, which address the “...
dispersion of the effect sizes...” are computable from a
frequentist perspective [76]. With respect to reservations
expressed regarding the status of the CORTICUS study
[29,74], we found no compelling evidence (Bayesian pre-
dictive P-value 0.074) that this trial was inconsistent
with the remaining (n = 7) trials.
Continued controversy and conventional wisdom [77]
would appear to mandate the conduct of a large-
(mega)-trial of this therapy in well-defined patient sub-
sets; an absolute treatment effect of 7.2%, control arm
risk of 54% and 90% power would suggest a total patient
number of greater than 2,000. This being said our pre-
dictive estimates were unable to suggest efficacy for
future ‘large’ trials, albeit the trial base from which these
estimates were made was small.
Conclusions
Although a null effect for mortality treatment efficacy of
low-dose corticosteroid therapy in severe sepsis and sep-
tic shock could not be excluded, there appears to be
credible evidence for shock reversal efficacy. Similarly,
although a null effect was not excluded, advantageous
effects of low-dose steroids had a high probability of
dependence upon patient age and underlying risk. Low-
dose steroid efficacy was not demonstrated in cortico-
trophin non-responders. Bayesian methods are apposite
to express uncertainty in efficacy estimates from meta-
analyses.
Key messages
￿ The efficacy of corticosteroids in patients with
severe sepsis and septic shock is uncertain despite
recent meta-analytic reviews.
￿ Bayesian methods are apposite to express uncer-
tainty in efficacy estimates from meta-analyses.
￿ The efficacy of low-dose corticosteroids had a high
probability of dependence upon patient age and
underlying risk; low-dose steroid efficacy was not
demonstrated in corticotrophin non-responders.
￿ Bayesian meta-analytic predictive estimates were
unable to suggest efficacy for future large trials.
￿ A null effect for mortality treatment efficacy of
low-dose corticosteroid therapy in severe sepsis and
septic shock could not be excluded.
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